S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion

Chenxu Shi, Timothy K. Cooper, Diane E. Mccloskey, Adam B. Glick, Lisa M. Shantz, David J. Feith

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neoplastic growth is associated with increased polyamine biosynthetic activity and content. Tumor promoter treatment induces the rate-limiting enzymes in polyamine biosynthesis, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC), and targeted ODC overexpression is sufficient for tumor promotion in initiated mouse skin. We generated a mouse model with doxycycline (Dox)-regulated AdoMetDC expression to determine the impact of this second rate-limiting enzyme on epithelial carcinogenesis. TetO-AdoMetDC (TAMD) transgenic founders were crossed with transgenic mice (K5-tTA) that express the tetracycline-regulated transcriptional activator within basal keratinocytes of the skin. Transgene expression in TAMD/K5-tTA mice was restricted to keratin 5 (K5) target tissues and silenced upon Dox treatment. AdoMetDC activity and its product, decarboxylated AdoMet, both increased approximately 8-fold in the skin. This enabled a redistribution of the polyamines that led to reduced putrescine, increased spermine, and an elevated spermine:spermidine ratio. Given the positive association between polyamine biosynthetic capacity and neoplastic growth, it was somewhat surprising to find that TAMD/K5-tTA mice developed significantly fewer tumors than controls in response to 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate chemical carcinogenesis. Importantly, tumor counts in TAMD/K5-tTA mice rebounded to nearly equal the levels in the control group upon Dox-mediated transgene silencing at a late stage of tumor promotion, which indicates that latent viable initiated cells remain in AdoMetDC-expressing skin. These results underscore the complexity of polyamine modulation of tumor development and emphasize the critical role of putrescine in tumor promotion. AdoMetDC-expressing mice will enable more refined spatial and temporal manipulation of polyamine biosynthesis during tumorigenesis and in other models of human disease.

Original languageEnglish (US)
Pages (from-to)1310-1318
Number of pages9
JournalCarcinogenesis
Volume33
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

Adenosylmethionine Decarboxylase
Keratin-5
Polyamines
Skin
Doxycycline
Neoplasms
Carcinogenesis
Ornithine Decarboxylase
Putrescine
Spermine
Transgenes
S-Adenosylmethionine
Spermidine
Tetradecanoylphorbol Acetate
Enzymes
Growth
Tetracycline
Keratinocytes
Carcinogens
Transgenic Mice

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Shi, Chenxu ; Cooper, Timothy K. ; Mccloskey, Diane E. ; Glick, Adam B. ; Shantz, Lisa M. ; Feith, David J. / S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion. In: Carcinogenesis. 2012 ; Vol. 33, No. 7. pp. 1310-1318.
@article{3548031b8321449ca3b19e419429ad9f,
title = "S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion",
abstract = "Neoplastic growth is associated with increased polyamine biosynthetic activity and content. Tumor promoter treatment induces the rate-limiting enzymes in polyamine biosynthesis, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC), and targeted ODC overexpression is sufficient for tumor promotion in initiated mouse skin. We generated a mouse model with doxycycline (Dox)-regulated AdoMetDC expression to determine the impact of this second rate-limiting enzyme on epithelial carcinogenesis. TetO-AdoMetDC (TAMD) transgenic founders were crossed with transgenic mice (K5-tTA) that express the tetracycline-regulated transcriptional activator within basal keratinocytes of the skin. Transgene expression in TAMD/K5-tTA mice was restricted to keratin 5 (K5) target tissues and silenced upon Dox treatment. AdoMetDC activity and its product, decarboxylated AdoMet, both increased approximately 8-fold in the skin. This enabled a redistribution of the polyamines that led to reduced putrescine, increased spermine, and an elevated spermine:spermidine ratio. Given the positive association between polyamine biosynthetic capacity and neoplastic growth, it was somewhat surprising to find that TAMD/K5-tTA mice developed significantly fewer tumors than controls in response to 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate chemical carcinogenesis. Importantly, tumor counts in TAMD/K5-tTA mice rebounded to nearly equal the levels in the control group upon Dox-mediated transgene silencing at a late stage of tumor promotion, which indicates that latent viable initiated cells remain in AdoMetDC-expressing skin. These results underscore the complexity of polyamine modulation of tumor development and emphasize the critical role of putrescine in tumor promotion. AdoMetDC-expressing mice will enable more refined spatial and temporal manipulation of polyamine biosynthesis during tumorigenesis and in other models of human disease.",
author = "Chenxu Shi and Cooper, {Timothy K.} and Mccloskey, {Diane E.} and Glick, {Adam B.} and Shantz, {Lisa M.} and Feith, {David J.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1093/carcin/bgs184",
language = "English (US)",
volume = "33",
pages = "1310--1318",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "7",

}

S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion. / Shi, Chenxu; Cooper, Timothy K.; Mccloskey, Diane E.; Glick, Adam B.; Shantz, Lisa M.; Feith, David J.

In: Carcinogenesis, Vol. 33, No. 7, 01.07.2012, p. 1310-1318.

Research output: Contribution to journalArticle

TY - JOUR

T1 - S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion

AU - Shi, Chenxu

AU - Cooper, Timothy K.

AU - Mccloskey, Diane E.

AU - Glick, Adam B.

AU - Shantz, Lisa M.

AU - Feith, David J.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Neoplastic growth is associated with increased polyamine biosynthetic activity and content. Tumor promoter treatment induces the rate-limiting enzymes in polyamine biosynthesis, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC), and targeted ODC overexpression is sufficient for tumor promotion in initiated mouse skin. We generated a mouse model with doxycycline (Dox)-regulated AdoMetDC expression to determine the impact of this second rate-limiting enzyme on epithelial carcinogenesis. TetO-AdoMetDC (TAMD) transgenic founders were crossed with transgenic mice (K5-tTA) that express the tetracycline-regulated transcriptional activator within basal keratinocytes of the skin. Transgene expression in TAMD/K5-tTA mice was restricted to keratin 5 (K5) target tissues and silenced upon Dox treatment. AdoMetDC activity and its product, decarboxylated AdoMet, both increased approximately 8-fold in the skin. This enabled a redistribution of the polyamines that led to reduced putrescine, increased spermine, and an elevated spermine:spermidine ratio. Given the positive association between polyamine biosynthetic capacity and neoplastic growth, it was somewhat surprising to find that TAMD/K5-tTA mice developed significantly fewer tumors than controls in response to 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate chemical carcinogenesis. Importantly, tumor counts in TAMD/K5-tTA mice rebounded to nearly equal the levels in the control group upon Dox-mediated transgene silencing at a late stage of tumor promotion, which indicates that latent viable initiated cells remain in AdoMetDC-expressing skin. These results underscore the complexity of polyamine modulation of tumor development and emphasize the critical role of putrescine in tumor promotion. AdoMetDC-expressing mice will enable more refined spatial and temporal manipulation of polyamine biosynthesis during tumorigenesis and in other models of human disease.

AB - Neoplastic growth is associated with increased polyamine biosynthetic activity and content. Tumor promoter treatment induces the rate-limiting enzymes in polyamine biosynthesis, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC), and targeted ODC overexpression is sufficient for tumor promotion in initiated mouse skin. We generated a mouse model with doxycycline (Dox)-regulated AdoMetDC expression to determine the impact of this second rate-limiting enzyme on epithelial carcinogenesis. TetO-AdoMetDC (TAMD) transgenic founders were crossed with transgenic mice (K5-tTA) that express the tetracycline-regulated transcriptional activator within basal keratinocytes of the skin. Transgene expression in TAMD/K5-tTA mice was restricted to keratin 5 (K5) target tissues and silenced upon Dox treatment. AdoMetDC activity and its product, decarboxylated AdoMet, both increased approximately 8-fold in the skin. This enabled a redistribution of the polyamines that led to reduced putrescine, increased spermine, and an elevated spermine:spermidine ratio. Given the positive association between polyamine biosynthetic capacity and neoplastic growth, it was somewhat surprising to find that TAMD/K5-tTA mice developed significantly fewer tumors than controls in response to 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate chemical carcinogenesis. Importantly, tumor counts in TAMD/K5-tTA mice rebounded to nearly equal the levels in the control group upon Dox-mediated transgene silencing at a late stage of tumor promotion, which indicates that latent viable initiated cells remain in AdoMetDC-expressing skin. These results underscore the complexity of polyamine modulation of tumor development and emphasize the critical role of putrescine in tumor promotion. AdoMetDC-expressing mice will enable more refined spatial and temporal manipulation of polyamine biosynthesis during tumorigenesis and in other models of human disease.

UR - http://www.scopus.com/inward/record.url?scp=84865180773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865180773&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgs184

DO - 10.1093/carcin/bgs184

M3 - Article

C2 - 22610166

AN - SCOPUS:84865180773

VL - 33

SP - 1310

EP - 1318

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 7

ER -